The FINEARTS-HF trial found that in adults with mild heart failure, finerenone did not provide eGFR benefits compared to a placebo. However, finerenone did lead to reductions in albuminuria and lower risks of new-onset albuminuria. Over 2.6 years of follow-up, there was no significant difference in the composite renal endpoint between the finerenone and placebo groups. Finerenone was found to be effective in reducing kidney disease risks for adults with chronic kidney disease and type 2 diabetes. Overall, finerenone caused an initial decline in eGFR but did not impact long-term eGFR trajectory while effectively reducing albuminuria.
Source link
Finerenone associated with lower albuminuria risks for adults with heart failure
